Cargando…
Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility
BACKGROUND: One approach to identify patients who meet specific eligibility criteria for target-based clinical trials is to use patient and tumor registries to prescreen patient populations. OBJECTIVE: Here we demonstrate that the Total Cancer Care (TCC) Protocol, an ongoing, observational study, ma...
Autores principales: | Li, Bin, Eschrich, Steven A, Berglund, Anders, Mitchell, Melissa, Fenstermacher, David, Danaee, Hadi, Dai, Hongyue, Sullivan, Daniel, Trepicchio, William L, Dalton, William S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379017/ https://www.ncbi.nlm.nih.gov/pubmed/28320689 http://dx.doi.org/10.2196/resprot.7289 |
Ejemplares similares
-
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022) -
Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013) -
Brentuximab Vedotin
Publicado: (2012) -
Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018) -
Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)